← Back
Data updated: Jun 28, 2026
ILMO Products Company
Pharma Pharmaceuticals
ILMO Products Company is a pharmaceutical company with 1 FDA-approved products.
2019
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
ILMO Products Company's Key Drugs
ILMO Products Company's core commercial portfolio centers on HELIUM, USP — its most strategically important drugs approved in the last 15 years.
ILMO Products Company's Recent FDA Approvals
New NDA/BLA approvals for ILMO Products Company over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
ILMO Products Company's Therapeutic Areas
Disease areas where ILMO Products Company has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
ILMO Products Company Pipeline Snapshot
Active clinical trials for ILMO Products Company across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • HELIUM, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2019-10-27
- Latest
- 2019-10-27
- Applications
- 1